Vaxcyte, Inc.
NASDAQ:PCVXBiotechnology
+$1.94 today
- Market cap
- $9.26B
- Beta
- 1.24
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$6.78
Volume 1.13M
Average 1.44M
PCVX Total Current Liabilities
All obligations due within one year.
Vaxcyte, Inc.NASDAQ: PCVX
Total Current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total current liabilities rises 75.6% from a year ago
Total current liabilities stood at $271.28M at the end of Q2 FY2026, up 75.6% from a year earlier and up 12.1% from the prior quarter. Over 3 fiscal years it compounded at +71.9% a year.
Context
- Total current liabilities amounted to 8.6% of total assets at the end of Q2 FY2026, up 4.0 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +75.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 205.75M USD
- Year-over-year change
- +46.8%
- 4-year CAGR
- +63.6%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 205.75M | +46.8% |
| FY2024 | 2024-12-31 | 140.18M | -3.5% |
| FY2023 | 2023-12-31 | 145.34M | +258.6% |
| FY2022 | 2022-12-31 | 40.53M | +41.1% |
| FY2021 | 2021-12-31 | 28.72M | — |
Total Current Liabilities vs competitors
How PCVX compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +75.6% is the highest of 9, against a peer median of -16.2%.
- Total current liabilities amounts to 8.6% of total assets for PCVX, versus a peer median of 16.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $32.65B USD | -13.5% | -4.3% | 16.2% | |
| Jun 2026 | £21.4B GBP | -23.4% | -2.2% | 34.9% | |
| Sep 2026 | $2.03B USD | +20.6% | -26.1% | 15.1% | |
| Mar 2026 | $342.46M USD | -18.9% | -42.8% | 32.8% | |
| Jun 2026 | $271.28M USD | +75.6% | +71.9% | 8.6% | |
| Sep 2026 | $98.09M USD | +71.7% | -50.2% | 16.1% | |
| Mar 2026 | €94.32M EUR | -11.2% | -30.4% | 25.3% | |
| Mar 2026 | $73.56M USD | -46.4% | -43.4% | 7.2% | |
| Mar 2026 | $34.37M USD | -30.4% | -34.1% | 14.0% | |
| Peer median (excluding PCVX) | — | -16.2% | -32.3% | 16.2% | |
Competitors are the stored peer set for PCVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 68.99M | 834.66M | 397.45M | 387.88M | 173.96M |
| Short-term Investments | 176.99M | 96.72M | 682.78M | 1.36B | 1.39B |
| Net Receivables | 0 | 0 | 3.61M | 20.66M | 46.56M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 5.96M | 20.12M | 2.8M |
| Total Current Assets | 256.35M | 942.56M | 1.1B | 1.79B | 1.63B |
| Property, Plant & Equipment (Net) | 35.91M | 31.65M | 110.62M | 270.15M | 491.72M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 27.12M | 26.55M | 162.68M | 1.39B | 883.13M |
| Tax Assets | 0 | 0 | 0 | 0 | 43.25M |
| Other Non-current Assets | 4.96M | 5.43M | 38.67M | 65.68M | 508K |
| Total Non-current Assets | 67.99M | 63.62M | 311.96M | 1.72B | 1.42B |
| Total Assets | 324.34M | 1.01B | 1.41B | 3.51B | 3.05B |
| Account Payables | 6.76M | 9.8M | 14.59M | 48.45M | 70.9M |
| Short-term Debt | 0 | 0 | 0 | 0 | 6.12M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.46M | 1.18M | 11.06M | 20.56M | 105.72M |
| Total Current Liabilities | 28.72M | 40.53M | 145.34M | 140.18M | 205.75M |
| Long-term Debt | 0 | 0 | 0 | 0 | 111.36M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 43.25M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 96K | 9K | 0 | 100K | (111.26M) |
| Total Non-current Liabilities | 11.6M | 12.04M | 22.11M | 65.32M | 154.7M |
| Total Liabilities | 40.32M | 52.57M | 167.45M | 205.5M | 360.46M |
| Common Stock | 56K | 82K | 98K | 128K | 134K |
| Retained Earnings | (298.64M) | (522.13M) | (924.39M) | (1.39B) | (2.15B) |
| Accumulated OCI | (241K) | (361K) | 179K | (3.87M) | 1.59M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 284.02M | 953.61M | 1.24B | 3.31B | 2.69B |
| Total Debt | 16.78M | 17.94M | 29.22M | 71.11M | 228.84M |
| Net Debt | (52.2M) | (816.72M) | (368.23M) | (316.77M) | 54.88M |
Vaxcyte, Inc.
NASDAQ:PCVX
Intrinsic Alpha fair value
Locked
Current Price
$58.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.